Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4349728 | 0.82 | KMT2A (0.45) | HPGDKMT2ANPC1SMN1; SMN2RAB9A | |
| SCHEMBL16675457 | 0.82 | KMT2A (0.45) | HPGDKMT2ANPC1SMN1; SMN2RAB9A | |
| SCHEMBL19328339 | 0.82 | KMT2A (0.45) | HPGDKMT2ANPC1RAB9AMAPT | |
| SCHEMBL29315637 | 0.82 | KMT2A (0.45) | HPGDKMT2ANPC1SMN1; SMN2RAB9A | |
| SCHEMBL28999622 | 0.82 | TP53 (0.51) | HPGDKMT2ANPC1SMN1; SMN2RAB9A | |
| SCHEMBL13828022 | 0.82 | MAPT (0.52) | HPGDNPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL3352182 | 0.82 | KMT2A (0.72) | HPGDKMT2ANPC1SMN1; SMN2RAB9A | |
| SCHEMBL1164883 | 0.80 | KMT2A (0.47) | HPGDKMT2ANPC1RAB9AMAPT | |
| SCHEMBL28578532 | 0.79 | KMT2A (0.49) | HPGDKMT2ANPC1SMN1; SMN2RAB9A | |
| SCHEMBL3988594 | 0.78 | KMT2A (0.41) | HPGDKMT2ANPC1SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119859144-B | Binuclear macrocyclic metronidazole metal complex and preparation method and application thereof | 山东理工大学 | 2025-06-24 | — | — | CN | disclosed |
| CN-119859144-A | Binuclear macrocyclic metronidazole metal complex and preparation method and application thereof | 山东理工大学 | 2025-04-22 | — | — | CN | disclosed |
| CN-116082365-B | 1,2, 4-Triazolo [3,4-b ] -1,3, 4-thiadiazole myricetin compound and preparation method thereof | 贵州大学 | 2024-11-05 | — | — | CN | disclosed |
| CN-116082365-A | 1,2, 4-triazolo [3,4-b ] -1,3, 4-thiadiazole myricetin compound and preparation method thereof | 贵州大学 | 2023-05-09 | — | — | CN | disclosed |
| EP-2222326-B2 | INHIBITORS OF MALT1 PROTEOLYTIC ACTIVITY AND USES THEREOF | VIB VZW (BE) | 2015-02-25 | — | — | EP | disclosed |
| EP-2222326-B1 | Inhibitors of MALT1-proteolytic activity and uses thereof | VIB VZW (BE) | 2012-04-18 | — | — | EP | disclosed |
| US-20110021548-A1 | INHIBITORS OF MALT1 PROTEOLYTIC ACTIVITY AND USES THEREOF | UNIVERSITEIT GENT (BE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021548-A1 | INHIBITORS OF MALT1 PROTEOLYTIC ACTIVITY AND USES THEREOF | UNIVERSITEIT GENT (BE) | 2011-01-27 | — | — | US | disclosed |
| US-20080045514-A1 | 3-Aryl-6-aryl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021548-A1 | INHIBITORS OF MALT1 PROTEOLYTIC ACTIVITY AND USES THEREOF | MMEL1, CTRL, ZFR | HPGD 3987/4885KMT2A 2852/4885NPC1 2692/4885 |
| US-20080045514-A1 | 3-Aryl-6-aryl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP3, CASP1, CASP2 | HPGD 2321/4885KMT2A 2333/4885NPC1 3262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.